Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors

Bibliography

• US Food and Drug Adminstration. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190787.htm, 2009 [Accessed 27 June 2011]
   Google Scholar
• Angiolillo DJ, Gibson CM, Cheng S, Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011;89:65-74
   PubMed Web of Science ®Google Scholar
• Abraham NS, Hlatky MA, Antman EM, ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienpyridines: a focued update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010;122:2619-33
   PubMed Web of Science ®Google Scholar
• Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 2011;4:365-80
   PubMed Web of Science ®Google Scholar
• Taubert D, von Beckerath N, Grimberg G, Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80:486-501
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Rekerbrink S, Klotz U, Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001;364:551-7
   PubMed Web of Science ®Google Scholar
• Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006;29:769-84
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Capodanno D, Pharmacodynamic effects of concomitant versus staggered clopidgogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv 2010;3:436-41
   PubMed Web of Science ®Google Scholar
• Campo G, Miccoli M, Tebaldi M, Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 2011;22:399-407
   PubMed Web of Science ®Google Scholar
• Kubica A, Kozinski M, Grzesk G, Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 2011;32:459-66
   PubMed Web of Science ®Google Scholar
• Bate ER, Lau WC, Angiolillo DJ. Clopidogrel-Drug Interactions. J Am Coll Cardiol 2011;57:1251-63
   PubMed Web of Science ®Google Scholar
• Kazui M, Nishiya Y, Ishtzuka T, Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9
   PubMed Web of Science ®Google Scholar
• Katrin S, Klein Teri E, Altman Russ B. "Clopidogrel pathway" Pharmacogenetics and genomics (2010). Article:20440227@PubMed. Available from: http://www.pharmgkb.org/pathway/PA154424674
   Google Scholar
• Mega JL, Close SL, Wiviott SD, Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312-19
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
   PubMed Web of Science ®Google Scholar
• Mistry SD, Trivedi HR, Parmar DM, Impact of proton pump inhibitors on efficacy of clopidogrel: review of evidence. Indian J Pharmacol 2011;43:183-6
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Tada H, Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Eur J Clin Pharmacol 2006;62:113-17
   PubMed Web of Science ®Google Scholar
• Kodaira C, Uchida S, Yamade M, Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [13C]-aminopyrine breath test. J Clin Pharmacol 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Ogilvie BW, Yerino P, Kazmi F, The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is metabolism-dependent inhibitor of CYP2C19: implications for coadminstration of clopidogrel. Drug Metab Dispos 2011;39:2020-33
   PubMed Web of Science ®Google Scholar
• Simon T, Steg PG, Becqumont L, Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction. Clin Pharmacol Ther 2011;90:561-7
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schomig E, van Werkum JW, Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17:110-16
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Massberg S, No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011;32:1605-13
   PubMed Web of Science ®Google Scholar
• Trenk D, Hochholzer W, Fromm MF, Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lewis JP, Fisch AS, Ryan K, Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther 2011;90:568-74
   PubMed Web of Science ®Google Scholar
• Hulot JS, Collet JP, Cayla G, CYP2C19 But Not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011;4:422-8
   PubMed Web of Science ®Google Scholar
• Tselepis AD, Tsoumani ME, Kalantzi KI, Influence of HDL and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy. J Thromb Haemost 2011;9:2371-8https://doi.org/10.1111/j.1538-7836.2011.04541.x doi:10.1111/j.1538-7836.2011.04541.x
   PubMed Web of Science ®Google Scholar
• Kwok CS, Loke YK. Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review. Drug Saf 2012;35:127-39
   PubMed Web of Science ®Google Scholar
• Harmsze AM, van Werkum JW, Taubert D, Esomepreazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel's active metabolite. Ann Pharmacother 2011;45:542-3
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009;54:1149-53
   PubMed Web of Science ®Google Scholar
• Cai J, Wu Q, Fan L, Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation [in Chinese]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2010;26:266-9
   PubMedGoogle Scholar
• Gremmel T, Steiner S, Seidinger D, The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests. J Cardiovasc Pharmacol 2010;56:532-9
   PubMed Web of Science ®Google Scholar
• Gremmel T, Steiner S, Seidinger D, The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Savarino V, Savarino E, Dulbecco P. Pharmacodynamic studies on PPIs: look carefully at the country of origin. Dig Liver Dis 2006;38:808-10
   PubMedGoogle Scholar
• Furuta T, Iwaki T, Umemura K. Influence of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010;70:383-92
   PubMed Web of Science ®Google Scholar
• Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010;8:810-23
   Google Scholar
• Siller-Matula JM, Jilma B, Schror K, Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost 2010;8:2624-41
   PubMed Web of Science ®Google Scholar
• Lima JP, Brophy JM. The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med 2010;8:81
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF, Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-17
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lai KH, Liu CP. Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. Gastroenterology 2011;140:791-8
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098
   PubMed Web of Science ®Google Scholar
• Valkhoff VE, Jong GW, van Soest EM, Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors. Aliment Pharmacol Ther 2011;33:77-88
   PubMed Web of Science ®Google Scholar
• Charlot M, Ahlehoff O, Norgaard ML, Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010;153:378-86
   PubMed Web of Science ®Google Scholar
• Kreutz RP, Stanek EJ, Aubert R, Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 2010;30:787-96
   PubMed Web of Science ®Google Scholar
• Charlot M, Grove EL, Hansen PR, Proton pump inhibitors use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011;342:d269
   PubMedGoogle Scholar
• Stockl KM, Le L, Zakharyan A, Risk of rehospitalisation for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010;170:704-10
   PubMed Web of Science ®Google Scholar
• Kreutz RP, Stanek EJ, Aubert R, Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 2010;30:787-96
   PubMed Web of Science ®Google Scholar
• van Boxel OS, van Oijen MG, Hagenaars MP, Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol 2010;105:2430-6
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Griffin MR, Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med 2010;152:337-45
   PubMed Web of Science ®Google Scholar
• Moukarbel GV, Signorovitch JE, Pfeffer MA, Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009;30:2226-32
   PubMed Web of Science ®Google Scholar
• Kwok CS, Nijjar RS, Loke YK. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Saf 2011;34:47-57
   PubMed Web of Science ®Google Scholar
• Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011;48:768-76
   PubMed Web of Science ®Google Scholar
• Linsky A, Gupta K, Lawler EV, Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772-8
   PubMed Web of Science ®Google Scholar
• Ng FH, Tunggal P, Chu WM, Esomeprazole Compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Tunggal P, Ng FH, Lam KF, Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. Am Heart J 2011;162:870-4
   PubMed Web of Science ®Google Scholar
• Wu CY, Chan FK, Wu MS, Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Gastroenterology 2010;139:1165-71
   PubMed Web of Science ®Google Scholar
• Dery JPP, Dery U, Rinfret S, The evaluation of the influence of statins and proton pump inhibitors on clopidogrel antiplatelet effect (SPICE) trial. J Am Coll Cardiol 2011;1:B219
   Google Scholar
• Parodi G, Marcucci R, Valenti R, High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306:1215-23
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305(11):1097-105
   PubMed Web of Science ®Google Scholar